arrow
T

Torsten Haferlach

mll munich leukemia laboratory
H指数:119
被引数:6.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS

TP53突变在高风险骨髓增生异常综合征(MDS)患者接受去甲基化药物治疗后的影响:来自国际MDS联盟VALIDATE数据库的分析

2026-11-140
OAAI
Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure

髓系肿瘤和骨髓衰竭中<i>BCOR</i>和<i>BCORL1</i>突变的截然不同后果

2026-11-130
OAAI
Deep learning predicts IDH1 mutation status in acute myeloid leukemia from bone marrow smears

深度学习预测骨髓涂片中的急性髓系白血病IDH1突变状态

2026-10-290
OAAI
Functional Classification of Monoallelic TP53 Mutations Refines Prognostic Stratification in Myelodysplastic Neoplasms

单等位基因TP53突变的功能分类细化了骨髓增生异常性肿瘤的预后分层

Blood
IF23.1
2026-10-060
OAAI
Two cases of an imatinib-sensitive PRKG2::PDGFRA-positive chronic myeloid neoplasm with basophilia

两例对伊马替尼敏感的PRKG2::PDGFRA阳性伴嗜碱性粒细胞增多慢性髓系肿瘤

Leukemia
IF13.4
2026-09-280
OAAI
Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms

Csnk1a1 E98突变重编程del(5q)骨髓增生异常性肿瘤的信号传导和代谢

Leukemia
IF13.4
2026-09-030
OA
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

基于低甲基化制剂治疗的反应对高风险骨髓增生异常综合征/肿瘤患者生存结局的影响:考虑基线临床-分子风险和移植状态的国际骨髓增生异常综合征联盟(icMDS)分析

2026-08-280
PRE
Somatic RUNX1 exonic deletions in myelodysplastic syndrome: A rare yet high‐risk recurrent genetic aberration

骨髓增生异常综合征中体细胞RUNX1外显子缺失:一种罕见但高风险的复发遗传异常

2026-08-210
OAAI
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution

基于分子演化的骨髓增生异常综合征预后评分

2026-05-262
PRE
Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma

克隆性造血的复发、TP53 扩增以及之前的来那度胺治疗是驱动多发性骨髓瘤患者 CAR-T 治疗后髓系障碍的因素。

Leukemia
IF13.4
2026-03-240
OAAI
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

演进至七难治性骨髓瘤涉及CD38、BCMA和GPRC5D的顺序性丢失

Leukemia
IF13.4
2026-02-170
OAAI
Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study

解析具有预后意义的NPM1突变成人急性髓系白血病的共突变模式——一项HARMONY研究

Leukemia
IF13.4
2026-01-140
OA
Image-based explainable artificial intelligence accurately identifies myelodysplastic neoplasms beyond conventional signs of dysplasia

基于图像的可解释人工智能能够准确识别髓系发育不良性肿瘤,超出常规发育不良迹象的范畴。

2025-12-110
OAAI